Daniel G. Anderson

Daniel G. Anderson

Top Cited Scholar 2026
Auto-generated profile, based on publicly available information

Daniel G. Anderson

David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, USA

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2009 in Nature Reviews Drug Discovery
Verified
Journal Article
Closed access
PDF file
KWKathryn A. Whitehead
Kathryn A. Whitehead
RLRobert Langer
Robert Langer
DADaniel G. Anderson
Daniel G. Anderson

27 April 2008 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
AAAkin Akinc
Akin Akinc
AZAndreas Zumbuehl
Andreas Zumbuehl
MGMichael Goldberg
Michael Goldberg
ELElizaveta S Leshchiner
Elizaveta S Leshchiner
VBValentina Busini
Valentina Busini
DADaniel G Anderson
Daniel G Anderson

3 June 2012 in Nature Nanotechnology
Verified
Journal Article
Open access
PDF file
HLHyukjin Lee
Hyukjin Lee
ALAbigail K. R. Lytton-Jean
Abigail K. R. Lytton-Jean
YCYi Chen
Yi Chen
KLKevin T. Love
Kevin T. Love
APAngela I. Park
Angela I. Park
DADaniel G. Anderson
Daniel G. Anderson
Nanoparticles are used for delivering therapeutics into cells1,2. However, size, shape, surface chemistry and the presentation of targeting ligands on the surface of nanoparticles can affect circulation half-life and biodistribution, cell-specific internalization, excretion, toxicity and efficacy3,4,5,6,7. A variety of materials have been explored for delivering small interfering RNAs (siRNAs)—a therapeutic agent that suppresses the expression of targeted genes8,9. However, conventional delivery nanoparticles such as liposomes and polymeric systems are heterogeneous in size, composition and surface chemistry, and this can lead to suboptimal performance, a lack of tissue specificity and potential toxicity10,11,12. Here, we show that self-assembled DNA tetrahedral nanoparticles with a well-defined size can deliver siRNAs into cells and silence target genes in tumours. Monodisperse nanoparticles are prepared through the self-assembly of complementary DNA strands. Because the DNA strands are easily programmable, the size of the nanoparticles and the spatial orientation and density of cancer-targeting ligands (such as peptides and folate) on the nanoparticle surface can be controlled precisely. We show that at least three folate molecules per nanoparticle are required for optimal delivery of the siRNAs into cells and, gene silencing occurs only when the ligands are in the appropriate spatial orientation. In vivo, these nanoparticles showed a longer blood circulation time (t1/2 ≈ 24.2 min) than the parent siRNA (t1/2 ≈ 6 min).

1 April 2019 in Molecular Therapy
Verified
Journal Article
Open access
PKPiotr S. Kowalski
Piotr S. Kowalski
Arnab RudraArnab Rudra
Arnab Rudra
LMLei Miao
Lei Miao
DADaniel G. Anderson
Daniel G. Anderson
MRNA has broad potential as a therapeutic. Current clinical efforts are focused on vaccination, protein replacement therapies, and treatment of genetic diseases. The clinical translation of mRNA therapeutics has been made possible through advances in the design of mRNA manufacturing and intracellular delivery methods. However, broad application of mRNA is still limited by the need for improved delivery systems. In this review, we discuss the challenges for clinical translation of mRNA-based therapeutics, with an emphasis on recent advances in biomaterials and delivery strategies, and we present an overview of the applications of mRNA-based delivery for protein therapy, gene editing, and vaccination.

23 June 2013 in Nature Biotechnology
Verified
Journal Article
Open access
PDF file
GSGaurav Sahay
Gaurav Sahay
WQWilliam Querbes
William Querbes
CAChristopher Alabi
Christopher Alabi
AEAhmed Eltoukhy
Ahmed Eltoukhy
SSSovan Sarkar
Sovan Sarkar
DADaniel G Anderson
Daniel G Anderson
Detailed analyses of siRNA delivery by lipid nanoparticles reveal major pathways of siRNA internalization and endosomal escape. Despite efforts to understand the interactions between nanoparticles and cells, the cellular processes that determine the efficiency of intracellular drug delivery remain unclear. Here we examine cellular uptake of short interfering RNA (siRNA) delivered in lipid nanoparticles (LNPs) using cellular trafficking probes in combination with automated high-throughput confocal microscopy. We also employed defined perturbations of cellular pathways paired with systems biology approaches to uncover protein-protein and protein–small molecule interactions. We show that multiple cell signaling effectors are required for initial cellular entry of LNPs through macropinocytosis, including proton pumps, mTOR and cathepsins. siRNA delivery is substantially reduced as ≅70% of the internalized siRNA undergoes exocytosis through egress of LNPs from late endosomes/lysosomes. Niemann-Pick type C1 (NPC1) is shown to be an important regulator of the major recycling pathways of LNP-delivered siRNAs. NPC1-deficient cells show enhanced cellular retention of LNPs inside late endosomes and lysosomes, and increased gene silencing of the target gene. Our data suggest that siRNA delivery efficiency might be improved by designing delivery vehicles that can escape the recycling pathways.

11 January 2010 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
KLKevin T. Love
Kevin T. Love
KMKerry P. Mahon
Kerry P. Mahon
CLChristopher G. Levins
Christopher G. Levins
KWKathryn A. Whitehead
Kathryn A. Whitehead
WQWilliam Querbes
William Querbes
DADaniel G. Anderson
Daniel G. Anderson
Significant effort has been applied to discover and develop vehicles which can guide small interfering RNAs (siRNA) through the many barriers guarding the interior of target cells. While studies have demonstrated the potential of gene silencing in vivo, improvements in delivery efficacy are required to fulfill the broadest potential of RNA interference therapeutics. Through the combinatorial synthesis and screening of a different class of materials, a formulation has been identified that enables siRNA-directed liver gene silencing in mice at doses below 0.01 mg/kg. This formulation was also shown to specifically inhibit expression of five hepatic genes simultaneously, after a single injection. The potential of this formulation was further validated in nonhuman primates, where high levels of knockdown of the clinically relevant gene transthyretin was observed at doses as low as 0.03 mg/kg. To our knowledge, this formulation facilitates gene silencing at orders-of-magnitude lower doses than required by any previously described siRNA liver delivery system.